First registration trial of tenapanor to treat hyperphosphatemia in ESRD patients on dialysis

Trial Profile

First registration trial of tenapanor to treat hyperphosphatemia in ESRD patients on dialysis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Tenapanor (Primary)
  • Indications Hyperphosphataemia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 08 Aug 2016 According to an Ardelyx media release, results from this trial are expected in the first quarter of 2017.
    • 08 Aug 2016 According to an Ardelyx media release, status changed from planning to recruiting.
    • 20 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top